Emerging Trends in Hematology – ASH 2023 Highlights
In December 2023, Medpace classic and malignant hematology experts attended the 65th American Hematology Society (ASH) conference in San Diego, CA. Learn more from Blythe…
Breast Cancer Awareness Month
[New Webinar] In recognition of Breast Cancer Awareness Month, we unite to promote screening and prevention of breast cancer, which affects one in eight women…
Medpace Strengthens Women’s Health Team
Medpace is pleased to announce that Dr. Aparna Shah has joined Medpace's Women's Health medical leadership team. With her addition, Medpace can offer Sponsors even…
[On-Demand Webinar] Liquid Biopsy in Oncology: Opportunities and Challenges
Join featured speakers from Medpace on September 8th, as they provide an overview of the current methodologies involved in liquid biopsies and their application for…
Medpace Welcomes Dr. DeWire-Schottmiller to the Hematology/Oncology Team
Dr. Mariko DeWire-Schottmiller is a board-certified pediatric hematologist/oncologist with 15 years of experience in clinical research, academia, and clinical oncology practice in Oncology and Neuro-oncology.…
The Evolving Landscape of Therapeutic and Diagnostic Radiopharmaceuticals
In a new article, experts from Medpace’s radiation oncology, imaging, regulatory, and operational teams discuss the growing space of radiopharmaceutical development.
Blythe Thomson, MD, Rejoins Medpace Bringing New Experiences and Insights from a Sponsor’s Perspective
Medpace is pleased to announce that Dr. Blythe Thomson has rejoined Medpace’s Hematology and Oncology medical leadership team after spending several years holding a variety…
Medpace Core Laboratories is Pleased to Announce A Successfully Completed Inspection by the FDA
Medpace Core Laboratories successfully completed a comprehensive inspection by the FDA on a late phase, registrational, oncology trial. The inspection concluded with no major or…
Infectious Diseases in the Immunocompromised Host
An in-depth look at infectious diseases including hematologic malignancies in immunocompromised patients and the unique challenges for clinical development.
4 Key Considerations for Designing Immuno-Oncology Trials
As more agents approach the clinic, it is imperative for researchers to consider the design and conduct of immuno-oncology clinical trials. Given the diversity of…